BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, BridgeBio Oncology Therapeutics, Inc. has 80.12M shares outstanding.

As of June 30, 2026, BridgeBio Oncology Therapeutics, Inc. maintains a current ratio of 4.69, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -68.99, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 69.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BridgeBio Oncology Therapeutics, Inc. generated - - in revenue and converted that into -3.18B in net income, yielding earnings per share of -102.94. EBITDA reached -3.46B, while operating income came in at -3.48B.

As of June 30, 2026, BridgeBio Oncology Therapeutics, Inc. holds 3.94B in cash and equivalents against 43.92M in total debt, resulting in a net debt position of -944.57M. Total book value stands at 5.65B, with working capital of 3.33B providing operational flexibility.

BridgeBio Oncology Therapeutics, Inc. produced -2.64B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.96M in capital expenditures, free cash flow totaled -2.65B - equivalent to -85.67 per share.